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Abstract
Objective: To determine the prevalence of Clostridium difficile colonization among patients who meet the 2017 IDSA/SHEA C. difficile
infection (CDI) Clinical Guideline Update criteria for the preferred patient population for C. difficile testing.
Design: Retrospective cohort.
Setting: Tertiary-care hospital in St. Louis, Missouri.
Patients: Patients whose diarrheal stool samples were submitted to the hospital’s clinical microbiology laboratory for C. difficile testing
(toxin EIA) from August 2014 to September 2016.
Interventions: Electronic and manual chart review were used to determine whether patients tested for C. difficile toxin had clinically
significant diarrhea and/or any alternate cause for diarrhea. Toxigenic C. difficile culture was performed on all stool specimens from
patients with clinically significant diarrhea and no known alternate cause for their diarrhea.
Results: A total of 8,931 patients with stool specimens submitted were evaluated: 570 stool specimens were EIA positive (+ ) and 8,361 stool
specimens were EIA negative (− ). Among the EIA + stool specimens, 107 (19% of total) were deemed eligible for culture. Among the EIA−
stool specimens, 515 (6%) were eligible for culture. One EIA+ stool specimen (1%) was toxigenic culture negative. Among the EIA− stool
specimens that underwent culture, toxigenic C. difficile was isolated from 63 (12%).
Conclusions: Most patients tested for C. difficile do not have clinically significant diarrhea and/or potential alternate causes for diarrhea.
The prevalence of toxigenic C. difficile colonization among EIA− patients who met the IDSA/SHEA CDI guideline criteria for preferred
patient population for C. difficile testing was 12%.
(Received 18 June 2018; accepted 13 August 2018; electronically published September 18, 2018)
Diagnosis of Clostridium difficile infection (CDI) poses a unique
challenge to clinicians because detection of C. difficile from a stool
specimen alone does not distinguish between colonization and
CDI.1 The “gold standard” method for C. difficile toxin detection
in stool specimens, the cell culture cytotoxicity neutralization
assay, is slow; toxin enzyme immunoassays (EIAs) are faster but
less sensitive. Nucleic acid amplification tests (NAATs) are both
sensitive and fast; however, because NAATs have greater analy-
tical sensitivity to detect C. difficile, NAATs may have poor
positive predictive value (PPV) for CDI.2
There is growing consensus that CDI diagnosis must combine
laboratory results with appropriate clinical criteria, including
presence of clinically significant diarrhea (CSD) and absence of
other causes of diarrhea or worsening of diarrhea beyond what
might otherwise be expected.3–6 To this end, the recently released
2017 Infectious Diseases Society of America (IDSA)/Society for
Healthcare Epidemiology of America (SHEA) Clinical Practice
Guidelines for CDI update emphasizes that the “preferred” patient
population for C. difficile testing is patients with unexplained
new-onset CSD, defined as ≥3 unformed bowel movements
within 24 hours. If testing cannot be limited to the preferred
testing population, the use of a stool toxin test as part of a
multistep diagnostic algorithm is the preferred method of testing,
and NAAT should not be used alone.7,8 If it is possible to limit
testing to the preferred testing population, it is recommended a
NAAT alone can be an acceptable testing method, but an
acceptable alternative is the use of a stool toxin test as part of a
multistep algorithm. Data are limited, however, on the prevalence
of C. difficile colonization among the preferred testing population;
this prevalence may affect the PPV of NAATs for CDI. Thus, the
first step toward determining the PPV of NAATs for CDI is to
address the knowledge gap surrounding the prevalence of C.
difficile colonization among patients who meet the IDSA/SHEA
guideline–preferred patient population for C. difficile testing.
To address this need, a retrospective cohort was assembled of
patients with stool specimens tested with a toxin EIA during
routine clinical care from patients with documented CSD and no
identifiable alternate causes of diarrhea. These stool specimens
were cultured for toxigenic C. difficile, and C. difficile isolates
underwent polymerase chain reaction (PCR) ribotyping to
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determine the prevalence of C. difficile colonization among
patients who met the IDSA/SHEA CDI clinical guidelines for the
preferred C. difficile testing population.
Methods
An aliquot from each stool specimen submitted to the Barnes-
Jewish Hospital (BJH, St. Louis, MO) clinical microbiology
laboratory for C. difficile testing has been collected and stored at
− 80°C, quantity pending, since August 2014 for quality
improvement purposes. Patients with stool specimens submitted
for C. difficile testing at BJH from August 2014 through Sep-
tember 2016 by toxin EIA (Alere TOX A/B II, Abbott, Lake Bluff,
IL) were eligible for inclusion. If a patient had >1 eligible stool
specimens during an admission, the first stool specimen collected
was used. Per hospital policy, only stool specimens that con-
formed to the shape of the container were tested for C. difficile. In
May 2015, a restriction was placed on repeat testing if the patient
had had a negative toxin EIA in the previous 4 days. The
Washington University Human Research Protection Office
approved this study.
Patients who did not have CSD or who had a potential
alternate cause of diarrhea at the time the stool specimen was
submitted for C. difficile testing were excluded. The hospital’s
medical informatics database was queried to obtain toxin EIA
results, microbiology results for detection of non–C. difficile
enteric pathogens from stool specimens, International Classifi-
cation of Disease, Ninth Revision, Clinical Modification (ICD-9-
CM) and International Classification of Disease, Tenth Revision,
Clinical Modification (ICD-10-CM) procedure and diagnosis
codes, and medications administered. Electronic data were used
to exclude patients if they had the following potential alternate
causes of diarrhea: history of inflammatory bowel disease, irritable
bowel syndrome, or colectomy in the previous 10 years; che-
motherapy in the 14 days before stool specimen collection;
hematopoietic cell transplant in the 180 days before stool speci-
men collection; alternate gastrointestinal pathogen isolated from
the stool specimen up to 7 days before or after the stool specimen
selected for this project was collected; tube feeds in the 48 hours
before collection or presence of an ostomy, ileostomy, or ileal
conduit; laxatives within 24 hours of specimen collection; pre-
vious history of CDI; or CDI antimicrobial treatment in the
10 days before and after specimen collection (eg, oral vancomy-
cin, oral or IV metronidazole, or oral fidaxomicin) for EIA
negative (EIA− ) stools only. All patients with EIA+ stool speci-
mens received CDI treatment. Patients with an EIA− stool spe-
cimens who received CDI antimicrobial treatment within 10 days
were excluded to ensure that patients with EIA− /toxigenic cul-
ture + stool specimens did not have CDI, which is the primary
concern in using NAATs to aid in the diagnosis of CDI. Manual
chart review was performed for all patients whose stool specimens
were not excluded during electronic screening to determine
whether the patients had any exclusion criteria that did not
appear in the electronic data and whether the patients had CSD.
All patients with CSD and no alternate cause of diarrhea were
included in the study. Patients with EIA+ /toxigenic culture +
stool specimens were considered to have CDI, and patients with
EIA− /toxigenic culture + stool specimens were considered colo-
nized and without CDI.2,9–12
Stool specimens were cultured for C. difficile according to
previously published methods.13 Briefly, a 1-g aliquot of the stool
specimen was heat shocked at 80°C for 10 minutes, inoculated
into cycloserine-cefoxitin mannitol broth with taurocholate and
lysozyme (Anaerobe Systems, Morgan Hill, CA), and incubated
anaerobically at 35°C. When turbid, the broth was inoculated
onto pre-reduced blood agar (BAP, Becton Dickinson, Franklin
Lakes, NJ). Clostridium difficile colonies were identified using
matrix-assisted laser desorption ionization-time of flight
(MALDI-TOF) mass spectrometry (MS) with the Vitek MS
platform (bioMerieux, Durham, NC). Clostridium difficile isolates
were evaluated for the presence of tcdA, tcdB, and binary toxin
genes (cdtA/cdtB) by multiplex PCR14–16 and underwent ribo-
typing. The ribotyping banding patterns were analyzed using
DiversiLab Bacterial Barcodes software (bioMerieux). Strains were
compared with the Cardiff-ECDC collection of C. difficile strains
for name assignment. Strains without a match in the Cardiff-
ECDC collection were assigned a Washington University (WU)
strain number.
Results
A total of 8,931 patients had stool specimens tested for C. difficile
during the study period (Fig. 1). Of these, 570 (6%) were EIA
positive (EIA+ ) and 8,361 (94%) were EIA negative (EIA− ). The
electronic screening process excluded 293 EIA+ stool specimens
and 5,809 EIA− stool specimens with potential alternate causes
of diarrhea, leaving 277 EIA+ and 2,552 EIA− stool specimens
eligible for chart review. The chart review process found an
additional 169 EIA+ stools and 2,037 EIA− stool specimens from
patients whose alternate cause of diarrhea was identified or for
whom study investigators were unable to find documentation of
CSD.
The remaining 107 EIA+ stool specimens (19% of all EIA +
stool specimens) and 515 EIA− stool specimens (6% of all EIA−
stool specimens) met inclusion and exclusion criteria and were
cultured for C. difficile. Among the EIA+ stool specimens, toxi-
genic C. difficile was isolated from 93 stool specimens (87%); 13
stool specimens (12%) could not be cultured due to insufficient
stool volume; and 1 stool specimen (1%) was toxigenic culture
negative. Among the EIA− stool specimens, C. difficile was not
isolated from 409 stool specimens (79%), nontoxigenic C. difficile
was isolated from 43 stool specimens (8%), and toxigenic C.
difficile was isolated from 63 stool specimens (12%). Binary toxin
was identified in 41 EIA+ /toxigenic culture + isolates (44%) and
9 EIA− /toxigenic culture + isolates (14%). The 3 most common
strains isolated from EIA+ stool specimens were ribotype 027
(n= 35, 38%), ribotype 106/174 (n= 14, 15%), and ribotype 002
(n= 10, 11%). The 3 most common toxigenic strains isolated
from EIA− stool specimens were ribotype 014/020 (n= 10, 16%),
followed by ribotype 027 (n= 8, 13%); ribotype 001 (n= 6, 10%),
and ribotype 106/174 (n= 6, 10%). None of the patients with
EIA− /toxigenic culture + stool specimens had a documented
microbiologically or clinically confirmed diagnosis of CDI within
30 days of the negative EIA.
Discussion
Using very strict criteria to ensure no potential alternate causes of
diarrhea, only 622 stool specimens (7%) submitted for C. difficile
testing were from patients with documented CSD and met the
IDSA/SHEA criteria for the preferred C. difficile testing popula-
tion.7,8 Among the stool specimens that were EIA+ , 19% met
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these criteria; among EIA− stool specimens, only 6% did. Not
surprisingly, toxigenic C. difficile was isolated from 93 of 94 (99%)
EIA+ stool specimens with sufficient stool for culture. This
finding suggests that toxin EIA has excellent specificity for
detecting patients with CDI among patients who meet the pre-
ferred C. difficile testing population definition. The most common
strain isolated from EIA+ stool specimens was ribotype 027,
which was identified at a proportion similar to that seen in 2010
at BJH.14 The 027 strain accounted for 35 of 41 strains (85%)
isolated from EIA+ stool specimens with binary toxin. Toxigenic
C. difficile was isolated from 63 (12%) of patients with EIA− stool
specimens. Compared with EIA+ /toxigenic culture + stool spe-
cimens, C. difficile isolated from EIA− /toxigenic culture + stool
specimens were less likely to have binary toxin. The strain dis-
tribution of toxigenic isolates from EIA− stool specimens was
different than that from EIA+ stool specimens. Ribotype 014/020
was the most common strain (16%), and ribotype 027 was the
second most common strain (13%).
Most importantly, although all patients included in this study
met the IDSA/SHEA criteria for the preferred C. difficile testing
population, the recovery of toxigenic C. difficile from these EIA−
stool specimens likely represented colonization and not CDI.
Patients were excluded if they received empiric treatment for CDI
(or were on metronidazole for other reasons), and no EIA− /
toxigenic culture + patients were diagnosed with CDI within
30 days of when the stool specimen selected for this study was
collected. The sensitivity of NAAT for detecting C. difficile from
diarrheal stool specimens submitted for C. difficile testing com-
pared to toxigenic culture in general has been found to be ~ 90%
to 100%.17 Toxigenic C. difficile was isolated from 156 stool
specimens, 63 of which were EIA− . Excluding the EIA+ stool
specimens without sufficient stool for culture and assuming that
all NAATs would be positive from all EIA + /toxigenic culture +
stool specimens, presumptively the PPV of NAAT for CDI from
this population would be 60%–64%, similar to the PPV of NAATs
for CDI seen when clinical presentation is taken into account.7,8,17
Even if it were assumed that toxigenic C. difficile would have been
recovered from the 13 EIA+ stool specimens with insufficient
stool for culture, the presumptive PPV of NAAT for CDI would
be 63%–66%.
This study had several limitations. All stool specimens were
initially submitted for C. difficile testing by clinicians and thus
may have been subject to selection bias. As a retrospective study,
it is possible that alternate, identifiable explanations for diarrhea
could have been missed. Based on the number of patients
excluded, we think that is unlikely. Notably, our definition for an
alternate explanation for diarrhea was very broad because we felt
it was more important to exclude a patient who did not neces-
sarily have an alternate explanation for diarrhea than risk mis-
classifying a patient in the other direction. Although our
exclusion criteria were very restrictive, they highlight the chal-
lenge of restricting C. difficile testing to patients who meet the
preferred testing population. We were also unable to determine
how many patients were excluded based on the lack of CSD alone;
many patients had >1 reason for exclusion or were excluded
using electronic data, from which CSD could not be determined.
Another limitation of the definition is that patients can simulta-
neously have CDI and an alternate explanation for diarrhea. Also,
we did not conduct NAATs, so the PPV of an NAAT among
patients who met the IDSA/SHEA guideline–preferred C. difficile
testing population criteria cannot be established and is based on
conjecture. However, the sensitivity of the NAAT for detection of
C. difficile from diarrhea stool specimens submitted for C. difficile
testing compared to toxigenic culture is well established, and this
Fig. 1. Results of screening and C. difficile toxigenic culture.
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study was not large enough to definitively establish the PPV of
NAAT among patients who meet the IDSA/SHEA guideline–
preferred C. difficile testing population criteria.
In conclusion, the IDSA/SHEA CDI clinical guideline update
recommendations for C. difficile testing are stratified based on
whether testing can be restricted to patients with unexplained and
new-onset CSD. The NAAT is recommended as a stand-alone test
if testing can be restricted to this population. The purpose of this
stratification is because NAATs can detect C. difficile colonization
among patients with diarrhea for other reasons. However, we
found that 12% of patients who met strict criteria for new-onset
CSD and no identifiable alternate cause of diarrhea were colo-
nized with C. difficile. Additional research is needed to determine
the optimal role for NAAT testing when there is clinical concern
for CDI and/or if other markers can differentiate between
C. difficile colonization and CDI.
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